- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03651349
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting for safety assessments (including the available plasma pharmacokinetic profile), the subjects will be allowed to receive (Z)-BP or placebo twice a day orally at the study site for 14 consecutive days and follow up on the 28th day after the last dose administration by a site visit. The study drugs (including placebo) will be administered at the study site by following the investigator's instructions to either perform blood sampling for pharmacokinetic evaluation or maximize the treatment compliance.
There will be 7 cohorts and subjects will be randomized into cohorts consisting of 8 subjects each (6 active and 2 placebo controls per cohort). Dose cohorts will be escalated sequentially from low to high dose (50 mg, BID; 100 mg, BID; 150 mg, BID; 225 mg, BID; 300 mg, BID; 400 mg, BID; 525 mg, BID) by following a modified Fibonacci sequence, and based on the decision of an independent DSMB at a set time point. Following all subjects of a cohort complete the safety and PK evaluation after receiving the last dose administration, a cohort at the next dose level will be launched if the DSMB does not identify significant safety concerns after reviewing safety data and PK profiles.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Hualien City, Taiwan, 97002
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject's age is no less than 20 years old.
Subjects whose body mass index (BMI) at screening is within a range of ≥18.5 kg/m2 and <25.0 kg/m2.
BMI = Body Weight (kg) / [Height (m)]2 And body weight is not less than 50 kg and 45 kg for males and females, respectively.
- Subject's medical history shows no contraindication to the test medications [hypersensitivity to (Z)-BP or any component of test and reference products].
- Subjects who are judged to be in good health by the investigator based upon the results of physical examinations (PEs) and chest X-ray (within 60 days prior to the first study dose), and all items of routine laboratory tests, including serum biochemistry, hematology and urinalysis, are within normal range as judged by the site. Assessment items of blood biochemistry include electrolytes (sodium, potassium, chloride, calcium, phosphorus), albumin, total cholesterol, total bilirubin, ALP, SGOT, SGPT, GGT, BUN, PT, APPT, serum creatinine, triglyceride, glucose, amylase, lipase, ACTH, aldosterone, cortisol, T3, free T4, TSH, and uric acid. Assessment items of hematology tests include red blood cell (RBC), white blood cell (WBC) and platelet count; differential WBC count including neutrophils, lymphocytes, monocytes, eosinophils, and basophils; hemoglobin, and hematocrit. Assessment items of urinalysis include appearance, gravity, pH, erythrocyte, leukocyte, epithelial cells, glucose, protein, ketones, and nitrite
- Female subjects show negative pregnancy test results within 30 days prior to the first study dose.
Subjects did not take any of the following medications in the specified durations:
- Any medication (except contraceptives) within 14 days prior to the first dose of the study
- Any enzyme inducer or inhibitor within 30 days prior to the first dose of the study
- Subjects understood and have signed the written informed consent form.
Exclusion Criteria:
- Subjects with any properly diagnosed disease within 30 days prior to the first dose of the study
- Subjects with a clinically significant hematological, endocrinal, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorders; subjects with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of drugs; subjects who have had any previous gastrointestinal surgery, except appendectomy if performed >90 days prior to the first dose of the study
- Subjects who have received any known hepatic or renal clearance-altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazine, clarithromycin, trolearndomycin, ketoconazole, miconazolem fluconazole, itraconazole) for a period of up to 30 days prior to the first dose of the study
- Subjects had participated in investigational drug trials and took any investigational drugs within 60 days prior to the first study dose.
- Subjects had blood donation for more than 250 mL within 60 days prior to the first dose of the study.
- Subjects had a history of drug abuse or alcohol abuse according to DSM IV criteria.
- Subjects who are smokers or have smoking history
- Subjects who cannot stop caffeine-intakes for 48 hours prior to the first study dose and during the entire study period.
- Subjects who are pregnant or lactating
- For enrollment of female subjects with child-bearing potential, the subject must be practicing sexual abstinence or be using and willing to continue to use a medically acceptable form of birth control for at least 1 month prior to screening (that period will extend to 3 months for oral contraceptive use) and for at least 30 days after the last dose of study drug. For a subject to be considered not to be of child-bearing potential, she must have been amenorrheic for at least 2 years, or must have had a hysterectomy, a bilateral tubal ligation, and/or a bilateral oophorectomy (as determined by the medical history). The male partner of a female study subject with childbearing potential must use a condom and ensure that his partner uses a suitable method of contraception as outlined above.
- Subjects who are inappropriate to participate in this study, as judged by the clinical investigator
Subjects who have been tested positive for the following tests:
- Human immunodeficiency virus (HIV)
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo control
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial.
The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
Other Names:
|
Experimental: 50 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 100 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 150 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 225 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 300 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 400 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
Experimental: 525 mg, BID
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
|
HK-001 is synthesized by PharmaCore Biotech Co., Ltd.
Synthetic (Z)-BP with high purity will be used in this proposed study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 48 days
|
The MTD will be determined by study definition as the highest dose level without significant safety and tolerability concern.
|
48 days
|
Dose Limiting Toxicities (DLT)
Time Frame: 48 days
|
In this study, the DLTs are defined as below:
|
48 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFBORAZ20141120
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Placebo control
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingDyslipidemiasKorea, Republic of
-
Vanda PharmaceuticalsCompleted
-
SIMR (Australia) Biotech Pty Ltd.CompletedPeripheral Neuropathic PainAustralia
-
PfizerNot yet recruiting
-
Affiris AGCompletedAlzheimer's DiseaseFrance, Austria, Croatia, Germany, Czech Republic, Slovakia
-
Cellphire Therapeutics, Inc.Department of Health and Human ServicesCompleted
-
McMaster UniversityCompletedMuscle Protein SynthesisCanada
-
Probi ABCompletedIrritable Bowel SyndromeNetherlands
-
Brigham Young UniversityDepartment of Health and Human Services; Florida State UniversityCompleted
-
Nature Cell Co. Ltd.CompletedAlzheimer DiseaseUnited States